Article Information
vol. 5 no. 196 196ra99
- Received for publication January 22, 2013
- Accepted for publication June 25, 2013
- .
Author Information
- Moshe Elkabets1,2,*,
- Sadhna Vora2,*,
- Dejan Juric2,*,
- Natasha Morse1,
- Mari Mino-Kenudson3,
- Taru Muranen4,
- Jessica Tao2,
- Ana Bosch Campos1,
- Jordi Rodon5,
- Yasir H. Ibrahim5,
- Violeta Serra5,
- Vanessa Rodrik-Outmezguine6,
- Saswati Hazra7,
- Sharat Singh7,
- Phillip Kim7,
- Cornelia Quadt8,
- Manway Liu9,
- Alan Huang9,
- Neal Rosen6,
- Jeffrey A. Engelman2,
- Maurizio Scaltriti1,† and
- José Baselga1,†
- 1Human Oncology & Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
- 2Massachusetts General Hospital Cancer Center, CNY 149, 13th Street, Charlestown, MA 02129, USA.
- 3Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
- 4Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA.
- 5Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Pg Vall d’Hebron, 119-129, Barcelona 08035, Spain.
- 6Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- 7Prometheus Therapeutics & Diagnostics, 9410 Carroll Park Drive, San Diego, CA 92121, USA.
- 8Novartis Pharma AG, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland.
- 9Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
- ↵†Corresponding author. E-mail: scaltrim{at}mskcc.org (M.S.); baselgaj{at}mskcc.org (J.B.)